Used primarily in the treatment of B-cell malignancies, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenström’s macroglobulinemia. It functions as a Bruton’s tyrosine kinase (BTK) inhibitor, blocking the signaling pathways that promote the survival and proliferation of malignant B-cells. This targeted therapy offers a more precise approach compared to traditional chemotherapy, often resulting in fewer side effects. It is administered orally, providing convenience for patients. Clinical trials have demonstrated its efficacy in improving progression-free survival and overall response rates, making it a valuable option for patients with relapsed or refractory forms of these cancers.